Blau Farmaceutica SA (BSP:BLAU3)

Q2 2025 Blau Farmaceutica SA Earnings Call Transcript

Aug 6, 2025 / 02:00 PM GMT

Release Date Price: R$9.31 (-2.81%)

Transcript

Key Points

Positve

Blau Farmaceutica SA (BSP:BLAU3) achieved a gross margin of over 40% in the quarter, marking the seventh consecutive quarterly improvement.
The company reported a recurring EBITDA of 122 million reais, representing an annual growth of 34%.
Blau Farmaceutica SA (BSP:BLAU3) is investing in expanding production capacity, with two new production lines completed and a third expected by the end of the fourth quarter.
The company is focusing on reducing reliance on a few high-ticket products by diversifying its product portfolio, which has improved efficiency and reduced volatility.
Blau Farmaceutica SA (BSP:BLAU3) is in a favorable financial position with low leverage and plans to use cash from Prothea to support strategic investments.

Negative

The company's revenue remained stable year-over-year, partly due to capacity constraints and unscheduled shutdowns at production plants.
Blau Farmaceutica SA (BSP:BLAU3) faced challenges in maintaining performance in the retail business unit due to a strong comparison base from the previous year.
The company decided not to proceed with a full acquisition of an asset due to high turnaround risks and financial efforts, including high interest rates.
There were operational challenges related to factory shutdowns and changes in product mix, which affected production efficiency.
Blau Farmaceutica SA (BSP:BLAU3) is experiencing a transition period with some pain points as it shifts its product mix and expands capacity.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BLAU3.SA - Blau Farmaceutica SA
Q2 2025 Blau Farmaceutica SA Earnings Call
Aug 06, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone and welcome to our earnings hall for the 2nd quarter of 2025 at Blau Pharmaceuticum. We are live at the Blau Studios in Sao Paulo with Marcelo, the CEO and founder, Douglas Ferris, the CFO and investor relations, and Mattos Fujizawa.

Our calls taking place in Portuguese with simultaneous translation into English. It will be available on our IR website soon. At the end of the presentation of the Q&A session with priority for the sell side analysts. For those who would like to submit questions, they miss select the raise hand feature on Zoom, located at the bottom center part. Other investors can send their questions by chat, then I'll pass the word on to Marcel to begin its part.

Thank you,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.